Notice: This CMS-approved document has been submitted - Philips ...
Notice: This CMS-approved document has been submitted - Philips ... Notice: This CMS-approved document has been submitted - Philips ...
CMS-1403-FC Measure Number and Title Measure Source Patients with CAD 7. Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) + AMA-PCPI ,* 8. Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction AMA-PCPI (LVSD) 9. Major Depressive Disorder (MDD): Antidepressant Medication During Acute NCQA Phase for Patients with MDD 10. Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic AMA-PCPI/NCQA Resonance Imaging (MRI) Reports 11. Stroke and Stroke Rehabilitation: Carotid Imaging Reports AMA-PCPI/NCQA 12. Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation AMA-PCPI/NCQA 14. Age-Related Macular Degeneration (AMD): Dilated Macular Examination AMA-PCPI/NCQA 18. Diabetic Retinopathy: Documentation of Presence or Absence of Macular AMA-PCPI/NCQA Edema and Level of Severity of Retinopathy 19. Diabetic Retinopathy: Communication with the Physician Managing Ongoing AMA-PCPI/NCQA Diabetes Care 20. Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician AMA-PCPI/NCQA 21. Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second AMA-PCPI/NCQA Generation Cephalosporin 22. Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac AMA-PCPI/NCQA Procedures) 23. Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When AMA-PCPI/NCQA Indicated in ALL Patients) 24. Osteoporosis: Communication With the Physician Managing Ongoing Care AMA-PCPI/NCQA Post-Fracture 28. Aspirin at Arrival for Acute Myocardial Infarction (AMI) AMA-PCPI/NCQA 30. Perioperative Care: Timing of Prophylactic Antibiotics - Administering AMA-PCPI/NCQA Physician 31. Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) AMA-PCPI/NCQA for Ischemic Stroke or Intracranial Hemorrhage 32. Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy AMA-PCPI/NCQA 33. Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge + AMA-PCPI/NCQA 34. Stroke and Stroke Rehabilitation: Tissue Plasminogen Activator (t-PA) AMA-PCPI/NCQA Considered 35. Stroke and Stroke Rehabilitation: Screening for Dysphagia AMA-PCPI/NCQA 36. Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services AMA-PCPI/NCQA 39. Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older AMA-PCPI/NCQA 40. Osteoporosis: Management Following Fracture AMA-PCPI/NCQA 41. Osteoporosis: Pharmacologic Therapy AMA-PCPI/NCQA 43. Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Isolated CABG Surgery 44. Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery 45. Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures) 46. Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility + 624 The Society of Thoracic Surgeons (STS) STS AMA-PCPI/NCQA AMA-PCPI/NCQA 47. Advance Care Plan AMA-PCPI/NCQA
CMS-1403-FC Measure Number and Title Measure Source 48. Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older 49. Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older 50. Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older AMA-PCPI/NCQA AMA-PCPI/NCQA AMA-PCPI/NCQA 51. Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation AMA-PCPI 52. Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy AMA-PCPI 53. Asthma: Pharmacologic Therapy AMA-PCPI 54. 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain AMA-PCPI/NCQA 55. 12-Lead Electrocardiogram (ECG) Performed for Syncope AMA-PCPI/NCQA 56. Community-Acquired Pneumonia (CAP): Vital Signs AMA-PCPI/NCQA 57. Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation AMA-PCPI/NCQA 58. Community-Acquired Pneumonia (CAP): Assessment of Mental Status AMA-PCPI/NCQA 59. Community-Acquired Pneumonia (CAP): Empiric Antibiotic AMA-PCPI/NCQA 64. Asthma: Asthma Assessment AMA-PCPI 65. Treatment for Children with Upper Respiratory Infection (URI) - Avoidance of Inappropriate Use NCQA 66. Appropriate Testing for Children with Pharyngitis NCQA 67. Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow 625 AMA-PCPI/American Society of Hematology (ASH) AMA-PCPI/ASH 68. Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy 69. Multiple Myeloma: Treatment With Bisphosphonates AMA-PCPI/ASH 70. Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry AMA-PCPI/ASH AMA-PCPI/American Society of Clinical 71. Breast Cancer: Hormonal Therapy for Stage IC-III estrogen Oncology Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer (ASCO)/National Comprehensive Cancer Network (NCCN) AMA- 72. Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients PCPI/ASCO/NCCN 76. Prevention of Catheter-Related Bloodstream Infections (CRBSI) - Central AMA-PCPI Venous Catheter Insertion Protocol 79. End-Stage Renal Disease (ESRD): Influenza Vaccination in Patients with AMA-PCPI ESRD 81. End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients + AMA-PCPI 82. End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal AMA-PCPI Dialysis + 83. Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia AMA-PCPI 84. Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment AMA-PCPI 85. Hepatitis C: HCV Genotype Testing Prior to Therapy AMA-PCPI 86. Hepatitis C: Consideration for Antiviral Therapy in HCV Patients AMA-PCPI 87. Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment AMA-PCPI 89. Hepatitis C: Counseling Regarding Risk of Alcohol Consumption AMA-PCPI
- Page 573 and 574: CMS-1403-FC requirements listed on
- Page 575 and 576: CMS-1403-FC a data submission vendo
- Page 577 and 578: CMS-1403-FC As we stated in the CY
- Page 579 and 580: CMS-1403-FC whether eligible profes
- Page 581 and 582: CMS-1403-FC ● Agree that the regi
- Page 583 and 584: CMS-1403-FC soon thereafter as is t
- Page 585 and 586: CMS-1403-FC Comment: We received ma
- Page 587 and 588: CMS-1403-FC Comment: One commenter
- Page 589 and 590: CMS-1403-FC additional 2.0 percent
- Page 591 and 592: CMS-1403-FC EHRs in 2009. The measu
- Page 593 and 594: CMS-1403-FC i. Overview and Summary
- Page 595 and 596: CMS-1403-FC voluntary consensus sta
- Page 597 and 598: CMS-1403-FC Comment: Several commen
- Page 599 and 600: CMS-1403-FC the AMA-PCPI should be
- Page 601 and 602: CMS-1403-FC are appropriate and do
- Page 603 and 604: CMS-1403-FC to make any changes to
- Page 605 and 606: CMS-1403-FC post the measures for p
- Page 607 and 608: CMS-1403-FC beneficiaries. We now h
- Page 609 and 610: CMS-1403-FC identified in Tables 15
- Page 611 and 612: CMS-1403-FC important difference in
- Page 613 and 614: CMS-1403-FC not use Measures #73 Ca
- Page 615 and 616: CMS-1403-FC measures, but which are
- Page 617 and 618: CMS-1403-FC with comment period. Ho
- Page 619 and 620: CMS-1403-FC ● Measure #41 Osteopo
- Page 621 and 622: CMS-1403-FC professional to simply
- Page 623: CMS-1403-FC measures. We consider t
- Page 627 and 628: CMS-1403-FC Measure Number and Titl
- Page 629 and 630: CMS-1403-FC ● Measure #120 CKD: A
- Page 631 and 632: CMS-1403-FC For the 2009 PQRI quali
- Page 633 and 634: CMS-1403-FC rule indicated that the
- Page 635 and 636: CMS-1403-FC Response: As suggested
- Page 637 and 638: CMS-1403-FC required for the measur
- Page 639 and 640: CMS-1403-FC ● Achievement of NQF
- Page 641 and 642: CMS-1403-FC These additional measur
- Page 643 and 644: CMS-1403-FC We did not include this
- Page 645 and 646: CMS-1403-FC Comment: Many commenter
- Page 647 and 648: CMS-1403-FC groups must have a part
- Page 649 and 650: CMS-1403-FC selected for inclusion
- Page 651 and 652: CMS-1403-FC Measure Title Measure S
- Page 653 and 654: CMS-1403-FC proposed HIV/AIDS measu
- Page 655 and 656: CMS-1403-FC set of denominator spec
- Page 657 and 658: CMS-1403-FC results, for this purpo
- Page 659 and 660: CMS-1403-FC informed decision-makin
- Page 661 and 662: CMS-1403-FC Comment: Several commen
- Page 663 and 664: CMS-1403-FC prior commitments that
- Page 665 and 666: CMS-1403-FC groups who successfully
- Page 667 and 668: CMS-1403-FC ● Eligible profession
- Page 669 and 670: CMS-1403-FC patients, families, and
- Page 671 and 672: CMS-1403-FC that have satisfactoril
- Page 673 and 674: CMS-1403-FC e-prescribing quality m
<strong>CMS</strong>-1403-FC<br />
Measure Number and Title Measure Source<br />
48. Urinary Incontinence: Assessment of Presence or Absence of Urinary<br />
Incontinence in Women Aged 65 Years and Older<br />
49. Urinary Incontinence: Characterization of Urinary Incontinence in Women<br />
Aged 65 Years and Older<br />
50. Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged<br />
65 Years and Older<br />
AMA-PCPI/NCQA<br />
AMA-PCPI/NCQA<br />
AMA-PCPI/NCQA<br />
51. Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation AMA-PCPI<br />
52. Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy AMA-PCPI<br />
53. Asthma: Pharmacologic Therapy AMA-PCPI<br />
54. 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain AMA-PCPI/NCQA<br />
55. 12-Lead Electrocardiogram (ECG) Performed for Syncope AMA-PCPI/NCQA<br />
56. Community-Acquired Pneumonia (CAP): Vital Signs AMA-PCPI/NCQA<br />
57. Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation AMA-PCPI/NCQA<br />
58. Community-Acquired Pneumonia (CAP): Assessment of Mental Status AMA-PCPI/NCQA<br />
59. Community-Acquired Pneumonia (CAP): Empiric Antibiotic AMA-PCPI/NCQA<br />
64. Asthma: Asthma Assessment AMA-PCPI<br />
65. Treatment for Children with Upper Respiratory Infection (URI) - Avoidance<br />
of Inappropriate Use<br />
NCQA<br />
66. Appropriate Testing for Children with Pharyngitis NCQA<br />
67. Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline<br />
Cytogenetic Testing Performed on Bone Marrow<br />
625<br />
AMA-PCPI/American<br />
Society of Hematology<br />
(ASH)<br />
AMA-PCPI/ASH<br />
68. Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients<br />
Receiving Erythropoietin Therapy<br />
69. Multiple Myeloma: Treatment With Bisphosphonates AMA-PCPI/ASH<br />
70. Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry AMA-PCPI/ASH<br />
AMA-PCPI/American<br />
Society of Clinical<br />
71. Breast Cancer: Hormonal Therapy for Stage IC-III estrogen<br />
Oncology<br />
Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer<br />
(ASCO)/National<br />
Comprehensive Cancer<br />
Network (NCCN)<br />
AMA-<br />
72. Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients<br />
PCPI/ASCO/NCCN<br />
76. Prevention of Catheter-Related Bloodstream Infections (CRBSI) - Central AMA-PCPI<br />
Venous Catheter Insertion Protocol<br />
79. End-Stage Renal Disease (ESRD): Influenza Vaccination in Patients with AMA-PCPI<br />
ESRD<br />
81. End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis<br />
in ESRD Patients +<br />
AMA-PCPI<br />
82. End-Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal AMA-PCPI<br />
Dialysis +<br />
83. Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C<br />
Viremia<br />
AMA-PCPI<br />
84. Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment AMA-PCPI<br />
85. Hepatitis C: HCV Genotype Testing Prior to Therapy AMA-PCPI<br />
86. Hepatitis C: Consideration for Antiviral Therapy in HCV Patients AMA-PCPI<br />
87. Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment AMA-PCPI<br />
89. Hepatitis C: Counseling Regarding Risk of Alcohol Consumption AMA-PCPI
Change language